Skip to search formSkip to main content

remimazolam

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BACKGROUND AND AIMS Remimazolam is an ultrashort-acting benzodiazepine. METHODS We performed a randomized double-blind… Expand
Is this relevant?
2017
2017
BACKGROUND Remimazolam is an ester-based short-acting benzodiazepine currently in clinical trials for IV administration. This… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
Remimazolam (CNS 7056) is a novel molecule, water soluble, ultra-short-acting intravenous BDZ under human research in protocols… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2015
2015
BACKGROUND This exploratory study was the first study of remimazolam in patients to assess the safety and efficacy of different… Expand
Is this relevant?
2015
2015
A robust and validated method based on ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC-MS/MS… Expand
Is this relevant?
2013
2013
BACKGROUND We performed the first multiple dose study of remimazolam designed to assess both the feasibility of maintaining… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 3
Is this relevant?
2012
2012
BACKGROUND A new benzodiazepine, remimazolam, which is rapidly metabolized by tissue esterases to an inactive metabolite, has… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
In this issue of Anesthesia & Analgesia, 2 research groups report their progress in the development of 2 novel anesthetic drugs… Expand
  • table 1
Is this relevant?
Review
2010
Review
2010
Remimazolam (CNS-7056) is a short-acting GABA(A) receptor agonist, under development by PAION, in collaboration with Japanese… Expand
Is this relevant?